About Renovaro
Renovaro is a publicly listed company based in Los Angeles (United States) founded in 2023. Renovaro is focused on AI-driven cancer diagnostics and therapeutics. It operates on a AI-as-a-Service and Professional Services model. Renovaro has completed 1 acquisition, including Predictive Oncology. Renovaro offers products and services including AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform. Its focus areas include Biotechnology, Precision Medicine, Technology and Artificial Intelligence.
Company details
Renovaro is engaged in leveraging AI technology for cancer diagnostics and precision medicine. The company operates in the healthcare and biotechnology sectors, offering solutions for biomarker discovery, early disease detection, and personalized treatments. Through its full-stack Bio-AI platform, Renovaro supports clinicians in improving patient outcomes across cancer and neurology care. Key initiatives include AI drug discovery, predictive analytics, and therapeutic development for specific genetic profiles. Strategic mergers and grants, such as with GEDiCube and BioSymetrics, enhance its capabilities in minimal residual disease detection and neurological diagnostics.
- Headquarters Los Angeles, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website renovarogroup.com
- Legal Name Renovaro Inc.
- Net Profit-$88.43 M (USD)-122.82as on Jun 30, 2024
- EBITDA-$27.27 M (USD)-39.95as on Jun 30, 2024
- Investments & Acquisitions
Products & Services of Renovaro
Renovaro offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform.
AI platform used for biomarker discovery in cancer.
Solutions tailored for personalized cancer treatment strategies.
Platform developed for neurological disease diagnosis support.
IPO & Listings of Renovaro
Renovaro is a publicly listed company on the NASDAQ with ticker symbol RENB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNASDAQ: RENB
- Listed entityRenovaro Inc.
- Exchange sectorHealth technology
- Share price$0.13 (-7.47% on the day) · 2025-09-29
- Market capitalisation$30.2M
- EPS (diluted, trailing year)$-0.47
- Volume (last session)3,821,506
- Analyst consensusNeutral
Financials of Renovaro
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$88.4M | -$27.3M | |
| 2023 | -$39.7M | -$19.5M | |
| 2022 | -$113.4M | -$22.7M | |
| 2021 | -$26.7M | -$23.0M | |
| 2020 | -$11.4M | -$11.6M |
Detailed financial statements for Renovaro
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Renovaro
Renovaro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Predictive Oncology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based platform for cancer diagnostics and precision medicine is utilized. | predictive-oncology.com | Eagan, United States | 2002 | Jan 2024 | •••• |
Complete acquisition details for Renovaro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Renovaro
2 dated milestones of Renovaro across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Renovaro is founded.
- Acquisition Acquires Predictive Oncology.
Top companies in Oncology
3 companies that operate in the same segment as Renovaro (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renovaro
Complete news archive for Renovaro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renovaro
Renovaro was founded in 2023.
Renovaro is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Renovaro is engaged in leveraging AI technology for cancer diagnostics and precision medicine. The company operates in the healthcare and biotechnology sectors, offering solutions for biomarker discovery, early disease detection, and personalized treatments. Through its full-stack Bio-AI platform, Renovaro supports clinicians in improving patient outcomes across cancer and neurology care. Key initiatives include AI drug discovery, predictive analytics, and therapeutic development for specific genetic profiles. Strategic mergers and grants, such as with GEDiCube and BioSymetrics, enhance its capabilities in minimal residual disease detection and neurological diagnostics.
Renovaro offers AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform.
Yes, Renovaro is publicly traded on NASDAQ under the ticker symbol RENB.
Renovaro has made 1 acquisition, including Predictive Oncology.